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provided it is propeBackground: Joint United Nations Programme on HIV/AIDS (UNAIDS) and Murray
et al. have both produced sets of estimates for worldwide HIV incidence, prevalence
andmortality. Understanding differences in these estimates can strengthen the interpret-
ation of each.
Methods: We describe differences in the two sets of estimates. Where possible, we
have drawn on additional published data to which estimates can be compared.
Findings: UNAIDS estimates that there were 6 million more people living with HIV
(PLHIV) in 2013 (35 million) compared with the Murray et al. estimates (29 million).
Murray et al. estimate that new infections and AIDS deaths have declined more
gradually than does UNAIDS. Just under one third of the difference in PLHIV is in
Africa, where Murray et al. have relied more on estimates of adult mortality trends than
on data on survival times. Another third of the difference is in North America, Europe,
Central Asia and Australasia. Here Murray et al. estimates of new infections are
substantially lower than the number of new HIV/AIDS diagnoses reported by countries,
whereas published UNAIDS estimate tend to be greater. The remaining differences are
in Latin America and Asia where the data upon which the UNAIDS methods currently
rely are more sparse, whereas the mortality data leveraged by Murray et al. may be
stronger. In this region, however, anomalies appear to exist between the both sets of
estimates and other data.
Interpretation: Both estimates indicate that approximately 30 million PLHIV and that
antiretroviral therapy has driven large reductions in mortality. Both estimates are useful
but show instructive discrepancies with additional data sources. We find little evidence
to suggest that either set of estimates can be considered systematically more accurate.
Further work should seek to build estimates on as wide a base of data as possible.
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S524 AIDS 2014, Vol 28 (Suppl 4)are computed in related but different ways and it should,
therefore, come as no surprise that, despite broad
similarities, there are some differences in the estimates.
However, whereasMurray et al. suggest that their approach
can unequivocally be preferred, we believe that it is
important to understand the differences that exist
between the two sets of estimates in order to know how
to interpret their respective findings. Given the import-
ance attached to estimates in global health, we also reflect
upon alternative ways in which country estimates can be
generated.Different approaches
The differences between the Murray et al. and the
UNAIDS approaches can be summarised by the data
upon which the estimates are based. UNAIDS derives
estimates using data on HIV prevalence in most settings
with generalised epidemics and some settings with
concentrated epidemics (Box 1). A model is fit to these
data in order to generate estimates of incidence, deaths
and other quantities. In some settings (mostly high-
income countries), estimates are configured to align with
case-report surveillance in others. Estimates are com-
puted by countries, with technical assistance from
UNAIDS, and results are tested for their consistency
with local surveillance and program data.
In contrast, Murray et al. base most of their estimates on
UNAIDS outputs that are then combined with their own
estimates of all-cause and cause-specific death rates.
Candidate epidemiological trajectories for a particular
country are generated, based on previously generated
results by UNAIDS but with Murray et al. applying their
own assumptions for, among other factors, HIV survival
rates and the distribution of incidence by age and sex.
Final estimates are generated by selecting from among the
candidate trajectories those that imply a better agreement
with their estimates of deaths. Estimates of mortality rates
are based on data from vital registration systems where
possible, and from other available data and model-based
extrapolations elsewhere. In lower-level epidemic settings
wherein AIDS cause-specific mortality is used, there is
some reclassification of deaths that is intended to account
for the misassignment of AIDS-related deaths to another
cause.
Thus, the UNAIDS and theMurray et al. estimates are not
independent, with the latter estimates relying on the same
epidemiologic models used by UNAIDS but with the
additional influence of their own estimates of mortality.Different results
These different approaches give reasonably similar results,
as has been highlighted previously [3]. However, there areinteresting differences: Murray et al. estimate that there
are fewer PLHIV than UNAIDS has reported, and
Murray et al. estimates suggest that recent reductions in
AIDS deaths have been more modest than UNAIDS has
reported. We consider each of these in turn.
Differences in the magnitude of the HIV
epidemic
For 2013, the number of PLHIV is 35 million in the
UNAIDS estimates and 29 million in Institute for Health
Metrics and Evaluation estimates. The 6 million person
difference is 17% of the UNAIDS total.
However, in the regions with the largest epidemics
(Southern, Eastern, Central and West Africa), where the
greatest attention of donors is focussed, the difference is
small; UNAIDS estimates 25 million PLHIV, whereas
Murray et al. estimate 23 million. This accounts for just
less than one third of the difference in the overall totals of
PLHIV globally.
In these areas with the largest epidemics, however, there
are important differences in the historic trajectory of new
infection and deaths, despite an overall agreement in
PLHIV. Numbers of deaths are smaller in theMurray et al.
estimates. This is likely because of different assumptions
made about natural HIV survival [i.e. without anti-
retroviral therapy (ART)]. UNAIDS bases its assumptions
on direct empirical measurements from long-running
population-based cohort studies [4] [11.1 years (8.7–14.2
years) for Eastern African cohorts and 11.6 years (9.8–
13.7 years) for Southern Africa] for 25–29-year olds,
which are also consistent with historical cohort studies in
Europe, North America and Australia [5] (10.9 years
(10.6–11.3 years) for 25–34-year olds)]. These same
survival times are applied across epidemic settings.
Murray et al. allow median survival to vary between
3.6 and 29.5 years, based on a new meta-analysis, and
permit survival rates to vary by sex, age and country in
any manner in order to best fit estimates of all-cause
mortality. Precedence is therefore given to their estimates
of deaths, which, in most of these countries, are modelled
based on indirect data sources, and therefore, potentially
subject to errors. This could lead to unsubstantiated
differences in survival rates across age, sex and country.
This survival schedule selection procedure may also have
contributed to the estimate by the Murray et al. that
during the 1990s HIV prevalence was higher among men
than in women. This has not been found in data from
cohort studies from that time [6–13] (Fig. 1), although
the comparison between estimates and data is somewhat
complicated by the different age groups for which results
are available.
There are greater proportionate differences between the
Murray et al. and UNAIDS estimates for other countries
outside Africa. Across North America, Europe, Central
Asia and Australasia, the total discrepancy in PLHIV is
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Box 1. Summary of Joint United Nations Programme on HIV/AIDS estimation
method
Joint United Nations Programme on HIV/AIDS (UNAIDS) provides guidance, support and tools for
countries to produce their own estimates of HIV and other indicators which are compiled into a set of
global statistics. These tools are continuously developed and updated in collaboration with a
reference group of epidemiologists, demographers and statisticians (www.epidem.org). Countries
determine whether to produce estimates for a whole country at once or to build this up from estimates
for regions and/or for multiple sub-populations. For each modelled country or region of a country, a
decision is made about whether the epidemic is ‘generalised’ (the epidemic has spread widely
throughout the general population) or ‘concentrated’ (the epidemic has remained largely confined
to key populations, such as sex workers and MSM).
For generalised epidemics, there are typically two main data sources: prevalence estimates among
women attending antenatal care (ANC) and prevalence estimates from nationally representative house-
hold based surveys. If a country does not have a population-based survey, it is then assumed that a bias
exists in the prevalence measured in the ANC vs. the true level in the general population, the value for
which is informed by a systematic analysis of countries that do have both types of prevalence data [38].
A model is fit to these data in a Bayesian framework that propagates uncertainty in the prevalence
measurements [39–41], making assumptions about the survival time with HIV based on a direct
analysis of cohort data [4] and incorporating programmatic information on the number of people on
ART. A sample of epidemic curves are so produced for each population and these are randomly
combined with epidemic curves from other populations to produce a set of estimated epidemic curves
for the whole country. Consistency with all-cause mortality [42] is guaranteed by adjusting, where
necessary, the non-HIV-related death rate. The total incidence rate for the whole population is
disaggregated by age and sex, according to empirically derived distributions [20]. Results for numbers
of new HIV infections, people living with HIV (PLHIV) and AIDS death are generated with estimated
measures of uncertainty that reflect the sampling errors in the prevalence data as well as assumed
variances imposed on multiple parameters. Those variances are not currently empirically derived and
arguably have been too tightly constrained.
In settings with concentrated epidemics wherein there exists a well functioning system by which new
HIV diagnoses are reported and counted, countries will normally follow their own procedures for
estimating new infections, PLHIV and AIDS death. In computing global total, UNAIDS produces sets of
estimates that correspond closely to these but these may not be published separately.
In other settings with concentrated epidemics, data on HIV prevalence among defined key groups and
estimates of the sizes of these populations are assembled and the model is fit to these. The population
size data will most often be derived empirically [30], or based on regional values [43–46], but a
consensus among local experts drawing on ancillary information sources can be used if other data are
not available. Additional epidemiological and behavioural data on these populations may be used to
specify a rate of population turnover or additional rate of mortality. Further adjustment can be made to
ensure a match in sex ratio of reported AIDS death in a vital registration system or if additional data
from surveys of ANC records indicate this is necessary.
In all settings, the impact of interventions are specified by fitting the model to program data on the
numbers on ART and women receiving prevention of mother-to-child transmission services. Assump-
tions are made on the impact of ART [47] and prevention of mother-to-child transmission [48] based on
the direct estimation of relevant parameters with large, high-quality, geographically varied longitudinal
data.
The models, data and actual files used for estimation are all available for free download from http://
apps.unaids.org/spectrum/. The methods in all the estimation process are fully described in a series of
open-access publications that are indexed at http://www.epidem.org/publications. Further infor-
mation on the process by which the UNAIDS methods are developed is available at www.epidem.org.1.7 million (UNAIDS PLHIV estimate 3.4 million vs.
Murray et al., 1.7million).This too accounts for almost one
third on the total global difference in the estimates. In these
regions, the epidemics are concentrated among those at
greatest risk of infection and Murray et al. assert that these‘concentrated epidemics have been systematically over-
estimated by a factor on average of more than two’.
Fortunately, however, many of these countries have strong
case-based surveillance data that can be used to investigate
these differences.
S526 AIDS 2014, Vol 28 (Suppl 4)
Tanzania Murray estimate
Uganda Murray estimate
Malawi Murray estimate
Zimbabwe Murray estimate
South Africa Murray estimate
Tanzania UNAIDS estimate
Ugands UNAIDS estimate
Malawi UNAIDS estimate
Zimbabwe UNAIDS estimate
South Africa UNAIDS estimate
Kisesa data (Tanzania)
Rakai data (Uganda)
Masaka data (Uganda)
Karonga data (Malawi)
Manicaland data (Zimbabwe)
0.5
1.0
2.0
1990 1994 1998 2002 2006 2010 2014
Umkhanyakude data (South Africa)
Fe
m
al
e:
 m
al
e 
H
IV
 p
re
va
le
nc
e 
ra
ti
o
Fig. 1. Female-to-male prevalence ratios in the Murray et al. estimates [ratio of numbers of women-to-men people living with
HIV (PLHIV), all ages] (solid coloured lines), in UNAIDS estimates (ratio of numbers of women to men PLHIV, all ages) (dashed
colour lines) and measurements in available population level survey data among 15–49-year olds (markers with grey connecting
lines). Note that the estimates based on data rely on an interpolation to provide a continuous time-series.Numbers of new diagnoses can be considered as a rough,
time-lagged proxy for HIV incidence. Broadly, number of
new diagnoses are expected to underestimate new
infections (as not all infected persons will seek HIV
testing), but the number of cases could overstate new
infections if there is double counting of patients (caused
by, for instance, their presentation at multiple sites) or if
many of the new cases were actually acquired abroad (for
instance, among migrants from higher prevalence
countries). In practice, in most places, measures are
taken in order to avoid double counting [16].
In Table 1, countries in Europe and North America are
ranked by the number of newly diagnosed HIV infections
they report. In general, Murray et al. estimates are
substantially less than the numbers of new cases reported
in a country, whereas UNAIDS estimates tend to be
greater. These differences are consistent over time
(Fig. 2a–d).
Some differences are quite extreme. For example, in the
UK, the Murray et al. estimate for the number of new
HIV infections among men (350 in 2010) is almost seven-
fold less than the estimate from the United Kingdom
Health Protection Agency for just MSM in England and
Wales (2300) [17].
Differences are also found in other countries with robust
surveillance systems, such as Australia and Japan (Fig. 2e
and f).These comparisons do not support the contention of
Murray et al. that their lower estimates of new infections
or PLHIV are more likely to be correct in these regions,
and perhaps others where additional data to cross-check
the estimates are not available. The UNAIDS estimate are
potentially consistent with not all newly infected persons
being diagnosed, but it is not possible to confirm the
accuracy of the estimates with these data.
The remainder of the global differences in the two
estimates of PLHIV comes largely from Asia Pacific (1.7
million discrepancy) and Latin America (630 000
discrepancy). In these settings, epidemics are also
concentrated and although there are less well developed
systems for reporting cases, many countries are assumed
to have good vital registration systems. In the regions
where vital registration systems are good (upon which
Murray et al. estimates are based) and estimates of
prevalence and size of risk groups (upon which UNAIDS
estimate are based) are thought to be less reliable, we agree
that estimates should rely more on mortality data in
addition to the epidemiological data. UNAIDS is already
doing this for Argentina, Mexico and Brazil in the latest
round of estimates [20]. Overall, the discrepancy in the
2013 numbers of new infections, PLHIV and deaths, in
those countries in Latin America and Asia with
concentrated epidemics but good vital registration
systems, amounts to 60 000 fewer new infections,
1.1 million fewer PLHIV and 55 000 fewer AIDS deaths
in the Murray et al. estimates compared with UNAIDS,
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Fig. 2. Comparison between Murray et al. and Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates of new
infections with case-report data in (a) Western Europe, (b) Eastern Europe and Central Asia, (c) United Kingdom, (d) United
States of America, (e) Australia and (f) Japan. Red line with squares is the estimate of newHIV infections fromMurray et al.; green
line with triangles is UNAIDS estimate of new infections; purple line with diamonds is the country-reported number of new HIV
diagnoses. UNAIDS estimates are not published for Japan, the United States of America or some European countries. Source:
[1,14,16,18,19].equivalent to about 3% of the overall UNAIDS estimates
for each indicator.
Nevertheless, other data – where they exist – in those
countries with good vital registration systems that have
not been incorporated into the Murray et al., estimates
can provide a useful check on derived estimates. For
instance, there have been two HIV prevalence surveys in
Dominican Republic, in 2002 and 2007 (samples sizes
26 217 and 55 170, respectively). Multiplying prevalence
estimates from those (1 and 0.8%, respectively [21]) by
corresponding population sizes estimates [22] gives
estimates of PLHIV aged 15–49 years of 46 000 and
40 000, respectively. Comparatively, Murray et al. esti-
mates for PLHIV of all ages, at 17 500 and 19 600,respectively, are less than half these values. In contrast, the
UNAIDS estimates for PLHIVof all ages, at 70 000 and
55 000, are greater which may be partly explained by
children and adults over 50 years living with HIV. In
Brazil, Murray et al. estimate 396 000 (263 000–515 000)
PLHIV, compared with the UNAIDS estimate of
726 000 (664 000–808 000); but the Brazilian govern-
ment reports [23] a total of 436 000 PLHIVeither in pre-
ART care or on ART – more than the point estimate in
Murray et al.
Arguably, these findings do not support the contention of
Murray et al., that their estimates are more likely to be
correct than any other estimates, even in these settings
where appropriate prevalence data are relatively sparse.
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(b)Difference in view of mortality trends over time
UNAIDS and Murray et al. estimates show that ART has
driven large declines in mortality, the most dramatic being
in southern and eastern Africa. However, the Murray
et al. estimates indicate a somewhat more modest
reduction in deaths than do those from UNAIDS.
Again, there are direct empirical data from population
cohorts in several settings in Africa that can be used to
assess the impact of ART (Fig. 3a–c). These data were
not incorporated into either the Murray et al. or the
UNAIDS estimates. These cohort data do indeed exhibit
strong reductions in the rate of AIDS deaths – falls on the
order of 50% reductions in mortality among PLHIV –
consistent in magnitude with the decline reported by
UNAIDS. It maybe the case, however, that the
intensively researched populations have benefitted by a
greater provision of ART than is available in the rest of
their countries, and so could have experienced larger
mortality reductions than at the national level.0
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Fig. 3. Empirical measures of death rates among people
living with HIV from cohort studies in (a) Uganda, (b)
Tanzania and (c) South Africa. Rates of men are in blue
and rates in women are in red. These are the reported age-
standardized mortality rates among HIV-infected individuals
for three periods: pre-ART, ART scale-up, and post-ART scale-
up, plotted as uniform over the calendar time to which those
definitions correspond [24]. ART, antiretroviral therapy.Conclusion
It is useful and welcome that two different methods have
been applied to estimate the same quantities. Most
striking is the overall similarity in the estimates, rather
than the differences – both show approximately 30
million people worldwide living with HIV and that
enormous gains in life years have been generated by ART.
It is inevitable that differences in the methods, related
though they are, will lead to some differences in the
results. We see this as an opportunity to investigate and
learn from how different approaches and assumptions can
affect results. Although we do not believe either set of
estimates will be uniformly correct, our further
investigations with additional empirical data do not lend
support to the central contention of Murray et al. that
their estimates should necessarily be preferred over others.
Rather, we find no evidence that either set of estimates
can be considered more accurate than the other, and
indeed both will – in places – exhibit discrepancies with
other data.
It is a significant and highly valuable contribution of
Murray et al., in that study and in their previous work
[25], to have produced estimates of breakdowns by
mortality cause. We agree that leveraging mortality data
can strengthen estimates of HIV, and other diseases, where
those data are available. However, we also believe that
estimation methods should appropriately balance this
with information from other epidemiological data
sources, including prevalence data, case-based surveil-
lance and program data. Without doing so, as we have
described, estimates can be generated that are clearly at
odds with robust data available in the countries, and such
contradictions will not assist planners in their evaluationof their interventions or in setting priorities. Future
work, for all those generating estimates in HIV, should
seek a fuller integration of these disparate data sources.
For its part, UNAIDS is seeking to include data from tests
for recent infection [26], case reports, vital registration
[27], programmes for prevention of mother-to-child
transmission and more details on ART programmes in
future estimates (audits of ART numbers, viral load
measurements in population-based surveys and country-
level data on survival and retention on ART), while also
S530 AIDS 2014, Vol 28 (Suppl 4)continuing to confront estimates with empirical data to
check the validity of its methods [28,29].
All methods for producing estimates have their limita-
tions. In this review, we have not attempted to be
systematic in comparing the two sets of estimates, but
have rather sought to identify and examine the largest and
most important differences. There will be examples in
both sets of estimates which seem to be falsified by other
data – which is a sign that neither set can be considered
perfect. This also underlines the difficulty in generating
estimates. The reliance, for instance, of the UNAIDS
method on the reported numbers on ART and its
assumptions of a uniform impact of ARTon transmission
and mortality risk may make it vulnerable to over-
estimating the impact of ART, where programs are not
able to deliver the same standard of care as has been
reported in studies or if there are any errors in reports of
numbers on ART. The reliance, exclusively until recently,
on the consistency in prevalence data in concentrated
epidemics, over time and of the veracity of empirically
derived, but nevertheless uncertain, estimates of sizes of
key populations [30] could also lead to biased results.
Nevertheless, the UNAIDS numbers and trends in new
infections and deaths seem directionally consistent with
other independent empirical data from cohort studies, for
example especially in the large generalised epidemics.
Meanwhile, theMurray et al.method suffers, by necessity,
on a reliance on uncertain models for mortality in most of
the settings with largest epidemics, and elsewhere is
subject to questions about the extent to which verbal
autopsy data can be relied upon [31,32] and the
difficulties of adjusting for misclassification of death
caused by AIDS.
There is increasingly a focus on country leaders taking
ownership of HIV programmes, and other public health
programmes, and there have been many calls for the
greater use of data in decision making. It is therefore
extremely helpful if the generation and use of data for
public decision making are led by countries. In a recent
editorial, Atun [33] calls for transparency and sharing of
the methods and data used to make estimates and an
emerging theme in programme planning and evaluating
is understanding process at a finer spatial scale [34]. In
this context, the UNAIDS approach of empowering
countries to construct their own estimates, increasingly at
sub-national level [35,36], with guidance on appropriate
methods and assumptions, with most datasets and models
freely accessible and continuously subject to peer review,
seems well placed. On the other hand, there are
advantages to synthesising data from multiple countries
together in order to produce an internally consistent
view of global health across disease and countries.
These different approaches are complementary and the
value that they each provide to country programme
planners can be enhanced through coordination and data
sharing.Wemay stand at the edge of a revolution in data sharing in
global health, as The United States President’s Emergency
Plan for AIDS Relief, The Global Fund for AIDS,
Tuberculosis and Malaria and other agencies open up
their records, and countries and international agencies
increase their efforts to distribute epidemiological data
[37]. This is an exciting time, and estimates and
evaluations will be strengthened through an iterative
scientific investigative process that should result in
meaningful gains in reliable information for country
programme planners.Acknowledgements
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